去纤苷作用以及功效

Defibrotide (alias: defibrotide sodium, defiteli) is an adenosine receptor agonist with multiple effects. The adenosine A1/A2 receptors of endothelial cells are involved in the regulation of endothelial cells and the response of endothelial cells to injury. Defibrotide can act on these receptors to produce a variety of downstream effects. Defibrotide can also reduce the expression of cell adhesion molecules on the surface of endothelial cells, thereby reducing the adhesion of leukocytes to vascular endothelial cells and reducing the inflammatory damage of endothelial cells.

Hepatic veno-occlusive disease (HVOD) is one of the serious complications after hematopoietic stem cell transplantation (HSCT), and the mortality rate in patients with severe HVOD can be as high as 100%. Defibrotide (defiteli) is a mixture of single-stranded oligonucleotides with anti-thrombotic and fibrinolytic effects. In recent years, multiple clinical research results have shown that defibrotide is a safe and effective drug for preventing and treating HVOD after HSCT.

The role and efficacy of defibrination:

In research evaluations, defibrinoside increased tissue plasminogen activator (t-PA) and thrombomodulin expression and decreased von Willebrand factor (vWF) and plasminogen activator inhibitor-1 (PAI-1) expression, thereby reducing EC activation and increasing EC-mediated fibrinolysis.

The effectiveness of defibrotide (defiteli) was evaluated through 3 research trials conducted on 528 patients. The subjects participating in the 3 trials were all patients diagnosed with VOD symptoms after HSCT and accompanied by abnormal liver or renal function. The results were based on 100 days after HSCT. Overall survival rate was used as an evaluation index. The results showed that the survival rate after 100 days of defibrotide treatment was 38% to 45%. However, data analysis found that the survival rate of HSCT patients who were expected to receive only supportive care or other drug intervention after 100 days was only 21% to 31%. Defibrotide has shown positive results in clinical trials.